BioNTech SE (BNTX)
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
BioNTech SE
No splits on record
Nothing in BNTX's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Revenue | $3.08B | $3.07B | $4.27B | $19.34B | $21.2B | $538.83M | $121.33M | $142.53M | $68.82M |
| YoY Growth | 0.2% | -28.0% | -77.9% | -8.8% | 3834.6% | 344.1% | -14.9% | 107.1% | - |
| Cost of Revenue | $688.72M | $604.74M | $670.1M | $3.35B | $3.25B | $66.25M | $19.44M | $15.29M | $10.41M |
| Gross Profit | $2.39B | $2.47B | $3.6B | $15.99B | $17.95B | $472.58M | $101.89M | $127.23M | $58.41M |
| Gross Margin | 77.6% | 80.3% | 84.3% | 82.7% | 84.7% | 87.7% | 84.0% | 89.3% | 84.9% |
| Research and Development | $2.26B | $2.52B | $1.99B | $1.72B | $1.06B | $720.59M | $253.05M | $159.83M | $95.52M |
| Selling, General, and Administrative | $780.03M | $669.2M | $623.06M | $604.63M | $365.55M | $121.22M | $48.37M | $30.24M | $32.95M |
| Other | $49.16M | $749.53M | $210.03M | -$452.8M | -$553.01M | -$277.18M | $3.24M | -$2.67M | -$1.6M |
| Total Operating Expenses | $3.09B | $3.94B | $2.83B | $1.87B | $872.98M | $564.63M | $304.66M | $187.4M | $126.87M |
| Operating Income (EBIT) | -$696.98M | -$1.47B | $771.31M | $14.12B | $17.08B | -$92.06M | -$202.77M | -$60.17M | -$68.46M |
| Operating Margin | -22.6% | -47.8% | 18.1% | 73.0% | 80.5% | -17.1% | -167.1% | -42.2% | -99.5% |
| Interest Expense | $15.24M | $14.7M | $8.67M | $17.68M | $6.29M | $2.08M | $1.89M | $1.99M | $728K |
| Interest Income | $281.8M | $0 | $392.48M | $52.92M | $1.75M | $1.63M | $1.96M | $2.3M | $2.3M |
| Other Income (Expense) | -$430.64M | $711.21M | $553.8M | $347.9M | -$265.22M | -$70.83M | $2.35M | $6.92M | -$27.51M |
| Income Before Tax (EBT) | -$1.13B | -$757.13M | $1.33B | $14.47B | $16.81B | -$162.89M | -$200.43M | -$53.25M | -$95.97M |
| Income Tax Expense | $91.54M | -$13.85M | $285.78M | $3.93B | $5.31B | -$179.87M | -$223K | $670K | $50K |
| Net Income | -$1.22B | -$743.27M | $1.04B | $10.54B | $11.5B | $16.98M | -$200.09M | -$53.65M | -$95.69M |
| Net Income Margin | -39.6% | -24.2% | 24.4% | 54.5% | 54.2% | 3.2% | -164.9% | -37.6% | -139.1% |
| Supplementary Data | |||||||||
| EPS | -4.51 | -2.77 | 3.87 | 38.08 | 43.87 | 0.06 | -0.85 | -0.21 | -0.38 |
| Diluted EPS | -4.51 | -2.77 | 3.83 | 37.09 | 41.21 | 0.06 | -0.85 | -0.21 | -0.38 |
| Weighted Average OS | 241.70M | 240.40M | 240.60M | 243.30M | 244.00M | 235.44M | 211.50M | 226.86M | 226.86M |
| EBITDA | -$701.6M | -$410.12M | $1.54B | $14.63B | $16.76B | -$117.42M | -$160.65M | -$26.76M | -$83.45M |
| EBITDA Margin | -22.8% | -13.3% | 36.1% | 75.7% | 79.1% | -21.8% | -132.4% | -18.8% | -121.3% |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Assets | ||||||||||
| Current Assets | ||||||||||
| Cash and Cash Equivalents | $8.57B | $10.91B | $13.03B | $15.5B | $1.89B | $1.35B | $579.99M | $459.72M | $192.28M | $339.27M |
| Short-Term Investments | $8B | $7.84B | $5.46B | $211.6M | $426.32M | $153.28M | $1.88M | $375K | $275K | $1.71M |
| Cash and Short-Term Investments | $16.57B | $18.75B | $18.49B | $15.71B | $2.32B | $1.51B | $581.87M | $460.1M | $192.55M | $340.98M |
| Accounts Receivable | $1.1B | $1.7B | $2.61B | $7.98B | $13.83B | $184.9M | $13.31M | $31.77M | $5.11M | $6.67M |
| Inventory | $123.62M | $316.5M | $399.62M | $491.12M | $561.39M | $71.61M | $13.49M | $6.47M | $4.33M | $3.65M |
| Other Current Assets | $235.41M | $237.63M | $313.82M | $303.77M | $126.69M | $100.44M | $17.13M | $13.68M | $9.87M | $3.16M |
| Total Current Assets | $18.03B | $21.01B | $21.82B | $24.49B | $16.84B | $1.86B | $625.8M | $501.58M | $211.86M | $355.41M |
| Long-Term Assets | ||||||||||
| Property, Plant & Equipment Net | $1.44B | $1.32B | $1.09B | $917.33M | $581.39M | $364.21M | $165.41M | $129.56M | $113.42M | $67.6M |
| Goodwill | $410.84M | $425.21M | $404.99M | $68.37M | $64.57M | $59.99M | $3.33M | $597K | $597K | $597K |
| Intangible Assets | $1.79B | $883.03M | $898.34M | $177.08M | $161.55M | $115.97M | $93.9M | $97.76M | $92.73M | $11.9M |
| Long-Term Investments | $2.78B | $1.4B | $1.31B | $89.6M | $23.8M | $0 | $0 | $20K | $21K | $74K |
| Deferred Tax Assets | $15.08M | $91.28M | $90.83M | $256.51M | $0 | $0 | $0 | $1K | $0 | $0 |
| Other Long-Term Assets | $85.99M | $40.33M | $93.17M | $7.26M | $16.09M | $187.91M | $2.68M | -$1K | -$2K | $85K |
| Total Long-Term Assets | $6.52B | $4.16B | $3.89B | $1.52B | $847.4M | $728.08M | $265.33M | $227.94M | $206.77M | $80.25M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $24.56B | $25.17B | $25.7B | $26.01B | $17.69B | $2.59B | $891.13M | $729.52M | $418.63M | $435.66M |
| Liabilities | ||||||||||
| Current Liabilities | ||||||||||
| Accounts Payable | $597.34M | $476.71M | $395.49M | $228.02M | $178.75M | $114.29M | $22.9M | $46.61M | $58.7M | $6.95M |
| Short-Term Debt | $58.29M | $44.13M | $31.39M | $40.22M | $145.12M | $3.35M | $2.04M | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $5.03M | $587.09M | $665.74M | $1.75B | $0 | $0 | $332K | $0 | $0 |
| Current Unearned Revenue | $843.02M | $329.46M | $394.71M | $86.14M | $207.91M | $0 | $0 | $73.77M | $86.41M | $37.39M |
| Other Current Liabilities | $820.46M | $1.96B | $904.49M | $2.28B | $1.61B | $552.57M | $118.01M | $88.44M | $96.89M | $18.94M |
| Total Current Liabilities | $2.39B | $2.82B | $2.31B | $3.3B | $3.89B | $677.02M | $154.33M | $140.9M | $177.13M | $63.27M |
| Long-Term Liabilities | ||||||||||
| Long-Term Debt | $33.39M | $239.86M | $213.39M | $196.85M | $191.71M | $170.82M | $16.51M | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $98.27M | $204.45M | $445.2M | $54.07M | $10.05M | $0 | $0 | $229.75M | $239.11M | $305.46M |
| Long-Term Deferred Tax Liabilities | $94.14M | $47.37M | $44.35M | $6.93M | $74.52M | $0 | $0 | -$229.75M | -$239.11M | $0 |
| Other Long-Term Liabilities | $261.98M | $173.5M | $67.81M | $47.03M | $232.6M | $122.67M | $108.49M | $0 | $239.11M | $31.34M |
| Total Long-Term Liabilities | $694.71M | $665.18M | $770.76M | $304.88M | $508.88M | $380.74M | $185.47M | $290.32M | $295.36M | $336.8M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.09B | $3.48B | $3.08B | $3.6B | $4.4B | $1.06B | $339.8M | $431.22M | $472.49M | $400.07M |
| Stockholders' Equity | ||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $289.23M | $277.74M | $277.74M | $277.74M | $275.17M | $275.17M | $259.53M | $215.95M | $186.31M | $3.65M |
| Retained Earnings | $20.06B | $21.34B | $22.08B | $21.04B | $11.04B | -$457.61M | -$474.62M | -$274.58M | -$220.93M | -$125.24M |
| Comprehensive Income & Other | -$1.63B | -$1.48B | -$1.1B | -$948.39M | $104.91M | $1.72B | $772.59M | $355.97M | -$20.45M | $155.63M |
| Other Stockholders' Equity | $1.12B | $72.06M | $261.42M | $1.09B | $1.97B | $1.72B | $766.42M | $355.97M | -$20.45M | $155.63M |
| Total Equity | $21.47B | $21.69B | $22.62B | $22.41B | $13.29B | $1.53B | $551.33M | $297.35M | -$55.07M | $34.04M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $946K | $1.22M | $1.55M |
| Total Liabilities and Equity | $24.56B | $25.17B | $25.7B | $26.01B | $17.69B | $2.59B | $891.13M | $728.57M | $417.41M | $434.11M |
| Supplementary Data | ||||||||||
| Total Debt | $298.61M | $283.99M | $244.78M | $237.07M | $336.84M | $268.24M | $82.91M | $60.57M | $56.25M | $29.79M |
| Net Debt | -$8.27B | -$10.62B | -$12.79B | -$15.26B | -$1.55B | -$1.08B | -$497.08M | -$399.15M | -$136.03M | -$309.48M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Operating Activities | |||||||||
| Net Income | -$1.22B | -$757.13M | $1.33B | $14.47B | $16.81B | -$162.89M | -$200.43M | -$53.25M | -$95.97M |
| Depreciation & Amortization | $410.79M | $332.93M | $204.89M | $137.75M | $84.01M | $43.24M | $37.87M | $24.56M | $11.76M |
| Deferred Income Tax | $79.3M | $0 | $0 | $0 | $0 | $0 | $0 | $1.17M | $29.35M |
| Stock-Based Compensation | $0 | $112.73M | $57.42M | $121.33M | $104.91M | $35.86M | $33.74M | $8.54M | $6.6M |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | $1.16B | $433.14M | $6B | $4.88B | -$13.19B | -$276.95M | $3.24M | -$20.93M | -$3.15M |
| Inventory | $190.91M | $83.23M | $91.5M | $70.27M | -$489.78M | -$55.64M | -$6.48M | -$1.4M | -$641K |
| Accounts Payable | -$776.71M | $847.28M | $132.84M | $95.74M | $1.69B | $228.58M | -$90.05M | -$23.43M | -$5.11M |
| Other Working Capital | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Working Capital Change | $577.12M | $1.36B | $6.23B | $5.05B | -$11.99B | -$104.01M | -$93.29M | -$45.76M | -$8.9M |
| Other Non-Cash Items | $641.29M | -$820.14M | -$1.81B | -$4.61B | -$4.02B | $172.72M | $335K | -$252K | -$1.57M |
| Net Cash from Operating | $489.34M | $232.04M | $6B | $15.17B | $993.97M | -$15.08M | -$221.76M | -$65M | -$58.72M |
| Investing Activities | |||||||||
| Capital Expenditures | -$803.76M | -$320.08M | -$279.41M | -$367.78M | -$142.44M | -$73.74M | -$43.12M | -$75.81M | -$64.51M |
| Acquisitions | $204.75M | $0 | -$376.38M | $0 | -$23.24M | -$67.7M | -$6.81M | $813K | $5.45M |
| Purchases of Investments | -$12.26B | -$13.82B | -$7.8B | -$53.4M | -$440.96M | $0 | $0 | $0 | $0 |
| Sales of Investments | $10.21B | $12B | $1.33B | $419.17M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | -$183.89M | -$644.16M | -$37.43M | -$25.81M | -$20.33M | -$36.31M | $789K | $5.8M |
| Net Cash from Investing | -$2.65B | -$2.33B | -$7.77B | -$39.44M | -$632.45M | -$161.77M | -$86.25M | -$75.02M | -$58.71M |
| Financing Activities | |||||||||
| Debt Repaid | - | $51.28M | $44.8M | $66.03M | $74.52M | -$158.31M | -$8.83M | -$3.86M | $1.84M |
| Common Stock Issuance | $0 | $0 | $0 | $123.45M | $179.76M | $841.25M | $419.4M | $404.12M | $0 |
| Common Stock Repurchases | $0 | $0 | -$825.05M | -$1.1B | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | -$541.06M | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$44.64M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Financing | -$56.77M | -$51.28M | -$869.85M | -$1.59B | $105.24M | $999.56M | $428.22M | $407.98M | -$1.84M |
| Forex Effect | $1.18B | $16.53M | $167.92M | $67.14M | $72.28M | -$50.61M | $0 | -$513K | -$27.73M |
| Net Change in Cash | -$1.04B | -$2.12B | -$2.47B | $13.61B | $539.05M | $772.1M | $120.21M | $267.45M | -$146.99M |
| Supplementary Data | |||||||||
| Operating Cash Flow | $489.34M | $232.04M | $6B | $15.17B | $993.97M | -$15.08M | -$221.76M | -$65M | -$58.72M |
| Capital Expenditure | -$187.9M | -$505.31M | -$788.18M | -$405.88M | -$172.05M | -$95.41M | -$79.43M | -$75.81M | -$64.51M |
| Free Cash Flow | $301.44M | -$273.27M | $5.21B | $14.76B | $821.92M | -$110.49M | -$301.2M | -$140.81M | -$123.23M |
| Cash at Beginning | $9.61B | $13.03B | $15.5B | $1.89B | $1.35B | $579.94M | $459.73M | $192.28M | $339.27M |
| Cash at End | $8.57B | $10.91B | $13.03B | $15.5B | $1.89B | $1.35B | $579.94M | $459.72M | $192.28M |